Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Gingival myeloid sarcoma (MS) refractory to induction chemotherapy is a rare clinical entity and can be treated with palliative radiation therapy (RT). However, there are few previously published reports of RT approaches for the treatment of gingival MS. We present a single institution retrospective observational study of adult patients treated with palliative RT for chemotherapy refractory gingival MS. A total of six patients diagnosed with gingival MS in the setting of relapsed or refractory acute myeloid leukemia treated with palliative RT were identified, with a median age of 66 (range 52–77). Patients were treated with radiation doses ranging from 5 to 20 Gy in 2–10 fractions. Two patients had adequate follow-up time to assess treatment response. One patient who was simulated with PET/CT experienced a local complete response, while the other patient required retreatment 2 months after initial treatment and experienced an eventual local partial response. Three patients experienced radiation mucositis, with one patient experiencing grade 5 toxicity attributed to concomitant treatment with the radiosensitizer hydroxyurea. We believe that this study can provide a practical reference point for other clinicians given the rarity of gingival MS requiring palliative radiation therapy as a clinical entity.

Cite

CITATION STYLE

APA

Lee, D. Y., Baron, J., Wright, C. M., Plastaras, J. P., Perl, A. E., & Paydar, I. (2021). Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.671514

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free